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Background: Detectable Kaposi’s sarcoma–associated herpesvirus (KSHV) DNA in blood and increased antibody titres may 
indicate KSHV reactivation, while the transmission of KSHV occurs via viral shedding in saliva.
Methods: We investigated the risk factors for KSHV DNA detection by real-time polymerase chain reaction in blood and by 
viral shedding in saliva, in 878 people aged 3 to 89 years of both sexes in a rural Ugandan population cohort. Helminths were de-
tected using microscopy and the presence of malaria parasitaemia was identified using rapid diagnostic tests. Regression modelling 
was used for a statistical analysis.
Results: The KSHV viral load in blood did not correlate with the viral load in saliva, suggesting separate immunological controls 
within each compartment. The proportions of individuals with a detectable virus in blood were 23% among children aged 3–5 years 
and 22% among those 6–12 years, thereafter reducing with increasing age. The proportions of individuals with a detectable virus in 
saliva increased from 30% in children aged 3–5 years to 45% in those aged 6–12 years, and decreased subsequently with increasing 
age. Overall, 29% of males shed in saliva, compared to 19% of females (P = .008). 
Conclusions: Together, these data suggest that young males may be responsible for much of the onward transmission of KSHV. 
Individuals with a current malaria infection had higher levels of viral DNA in their blood (P = .031), compared to uninfected individ-
uals. This suggests that malaria may lead to KSHV reactivation, thereby increasing the transmission and pathogenicity of the virus.
Keywords. Kaposi’s sarcoma herpesvirus DNA; risk factors; Uganda.
Kaposi’s sarcoma-associated herpesvirus (KSHV) causes 
Kaposi’s sarcoma (KS), multicentric Castleman disease, and 
primary effusion lymphoma [1–6]. The prevalence of KSHV 
and incidence of KS both vary geographically [7–9], and are en-
demic in sub-Saharan Africa [10, 11].
Salivary exchange is the main route of transmission of KSHV, 
normally occurring in early childhood and increasing with age 
[12–15]. In a rural population cohort in Uganda (the general 
population cohort [GPC]), we previously reported KSHV in-
fections in children as young as 1 year [11, 16]. In addition to 
viral shedding in saliva, viral DNA detection in blood and in-
creased antibody titres to lytic antigens are markers of frequent 
KSHV reactivation [13]. The KSHV-associated oncogenesis 
and progression of diseases, as well as virus transmission, are all 
thought to be related to virus reactivation [17].
Viral DNA detection in blood has been associated with KS di-
sease risk and progression [18–21]. Additionally, treatment with 
combined antiretroviral therapy of KS patients living with acquired 
immunodeficiency syndrome has been shown to reduce the KSHV 
load in blood to undetectable levels [18, 22]. Determinants of KSHV 
DNA detection in blood among KSHV-seropositive people in the 
general population are not well understood. The presence of a viral 
load in plasma and peripheral blood mononuclear cells (PBMCs) 
has been reported mainly in high-risk groups, such as individuals 
living with human immunodeficiency virus (HIV) and patients 
with KSHV-related diseases [18, 23–27]. A  few studies have re-
ported KSHV viral loads in blood donors (adults) in nonendemic 
areas [28–30] and another study reported plasma viral loads in a 
population-based HIV survey in an endemic area [31].
Environmental factors may contribute to high KSHV trans-
mission in endemic areas. We have previously shown that 
KSHV seroprevalence is associated with malaria parasitaemia 
[16], higher malaria antibody titres [32], and helminth infec-
tions [33, 34]. We and others have reported that KSHV shed-
ding in saliva is more common in males, compared to females 
[35, 36], but no study has investigated KSHV viral loads in both 
blood and saliva in the same individuals within a population-
based study in a KSHV-endemic area.
This study investigated KSHV viral DNA detection in PBMCs 
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from the GPC: a longstanding cohort in rural, southwestern 
Uganda. We also determined the risk factors associated with 
viral DNA detection and levels in PBMCs and in saliva, and the 
relationship between viral DNA detection in PBMCs and saliva 
and KSHV antibody levels in plasma.
METHODS
Study Population and Ethical Approvals
This work was carried out within the GPC. The GPC is a 
community-based cohort of 22 000 people in 25 adjacent vil-
lages in southwestern Uganda. It was established in 1989 to 
carry out HIV research; participants from the GPC have been 
followed ever since. Between July 2017 and November 2017, we 
nested a cross-sectional study within the GPC, enrolling 975 
KSHV-seropositive (tested previously [32]) individuals who 
were living without HIV and aged 3 to 89  years. Participants 
were selected randomly after stratification for age, sex, and 
household. Blood, stool, and saliva samples were collected from 
these individuals. PBMCs and plasma were obtained from blood 
for immunological and virological analyses. Stool samples were 
used for helminth diagnoses, while saliva samples were used 
for KSHV viral DNA detection and quantification. Socio-
demographic data were collected using standard question-
naires. This study was approved by the Uganda Virus Research 
Institute  (UVRI) Research and Ethics Committee (reference 
number GC/127/16/09/566), the Uganda National Council 
for Science and Technology (reference number HS2123), and 
the London School of Hygiene & Tropical Medicine (LSHTM) 
Ethics Committee (reference number 11881). Written informed 
consent was obtained from all adults aged 18 years and above. 
Parents or guardians consented for children below 18 years; ad-
ditionally, children aged 8–17 years provided written assent.
Laboratory Procedures
KSHV DNA was quantified in PBMCs and saliva from 878 
KSHV-seropositive individuals. About 2 million PBMCs and 
saliva pellets were processed for DNA extraction. Study parti-
cipants were instructed to rinse with 5 mL of Listerine mouth-
wash, emptying it, as well as saliva, in a falcon tube. Aliquots 
(of 1 mL each) of saliva were spun at 13 000 relative centrifugal 
force for 10 minutes to form saliva pellets. Thereafter, the super-
natant was removed, and the saliva pellet was stored at −80oC. 
Genomic DNA was extracted from PBMCs and saliva pellets 
using a QIAamp blood kit (Qiagen, Valencia, CA), following 
the manufacturer’s instructions. KSHV DNA was quantified 
using real-time polymerase chain reaction, following proced-
ures previously reported [13, 37, 38]. KSHV DNA was detected 
using primers and a probe specific to the K6 gene region [39]. 
Additionally, the numbers of cellular equivalents in PBMCs 
were determined using a quantitative assay specific to human 
endogenous retrovirus 3 [39], which is present in 2 copies per 
genomic cell. Raw copies were reported for saliva KSHV DNA. 
Samples were amplified in triplicate; the samples that were posi-
tive in 1 or 2 reactions in the KSHV K6 assay were designated as 
qualitative positives. The sensitivity of the K6 assay is 3 copies.
Using an in-house Luminex assay and enzyme-linked immu-
nosorbent assay, as previously reported [40–42], plasma sam-
ples were tested for immunoglobin G (IgG) antibody levels to 
the KSHV K8.1 (lytic) and open reading frame (ORF) 73 (la-
tent) antigens. The enzyme-linked immunosorbent assay was 
used to confirm serostatus, while the Luminex assay was used to 
determine antibody levels, due to its wider dynamic range. The 
presence of malaria parasitaemia was diagnosed using rapid di-
agnostic tests (ONE STEP Malaria HRP-II [Plasmodium falcip-
arum] and pLDH [Plasmodium species] Antigen Rapid Test). 
A  single stool sample was provided by each participant. This 
was analyzed for helminths (Schistosoma mansoni, Ascaris 
lumbricoides, Tichuris trichiura, Trichostrongylus spp, and hook-
worm) using the Kato Katz microscopy method, following the 
manufacturer’s instructions. Details of this procedure have been 
reported elsewhere [43, 44].
Statistical Analysis
A statistical analysis was carried out using STATA version 13 
(Statacorp, College Station, TX). Graphs were drawn using 
STATA and GraphPad Prism version 6.  Qualitative, positive 
samples were given a constant value of 0.04 for saliva and 0.5 
for PBMCs, which were below the values of the lowest quali-
fied samples for a quantitative analysis. Viral load levels were 
log
10
 transformed. First, the risk factors associated with viral 
DNA detection (as a categorical outcome variable) in saliva and 
blood, separately, were obtained using logistic regression mod-
elling. Thereafter, the risk factors associated with increasing 
levels of viral DNA (as a continuous outcome variable) in saliva 
and in blood were separately determined using linear regression 




We tested 878 individuals for KSHV viral DNA; 49% (410/834) 
were males and 3% (27/840), 11% (95/840), 13% (110/840), 
8% (67/840), 17% (139/840), 14% (121/840), 14% (118/840), 
9% (74/840), and 11% (89/840) were aged 3–5, 6–12, 13–18, 
19–25, 26–35, 36–45, 46–55, 56–65, and 66–89 years, respec-
tively (Table 1). The proportions of individuals with malaria 
parasitaemia were 4% (34/834) overall and 11% (13/120) 
among children aged 3–12  years. Previously, we reported an 
annual malaria prevalence of 18% in the same population 
[16]. The lower prevalence of malaria infection in this study 
might be attributed to sample collection during the dry season. 
Hookworm was the most prevalent helminth, at 15% (104/686), 
followed by Schistosoma mansoni and Ascaris lumbricoides at 
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may have slightly underestimated the true prevalence of hel-
minths, because a single-sample test was used rather than a 
triple-sample test.
Blood and Saliva DNA Detection and Levels 
We did not observe a correlation between KSHV DNA 
copy numbers in PBMCs and DNA copy numbers in saliva 
(Figure 1). The proportion of individuals with detectable viral 
DNA in saliva was higher than the proportion of people with 
the detectable viral DNA in PBMCs (Figure 2). Children had 
the highest proportions of detectable viral DNA in PBMCs 
(Figure 2A) and in saliva (Figure 2B), decreasing with 
increasing age in adults. The trends were similar for females 
and males, with males having higher proportions of detectable 
viral DNA in saliva.
Associations Between Risk Factors and DNA
The proportion of individuals with detectable viral DNA in 
PBMCs decreased with increasing age; this trend was significant 
even after adjusting for sex and parasite infections (Table 2). 
Individuals infected with malaria parasites had higher levels 
of KSHV DNA in blood, compared to malaria-uninfected in-
dividuals (adjusted regression coefficient 0.79 [confidence 
interval [CI], .07–1.50]; P = .031; Table 3). We observed no sta-
tistically significant associations with other measured risk fac-
tors, including age, sex, hookworm infection, and S.  mansoni 
infection (Table 3).
Associations Between Risk Factors and DNA in Saliva
Overall, males had a higher risk of shedding viral DNA, com-
pared to females (adjusted odds ratio 1.63 [CI,  1.14–2.34]; 
P = .008; Table 4). Similar to PBMCs, the proportion of parti-
cipants with shedding in saliva diminished with increasing age, 
even after adjusting for sex and parasite infections (P = .0001; 
Table 4). Additionally, compared to females, males had higher 
Table 1. General Characteristics and Parasite Infection Status
Sex, males 49% (410/834)
Age, mean (range) 36 (3–89)
Age groups
 2–5 3% (27/840)
 6–12 11% (95/840)
 13–18 13% (110/840)
 19–25 8% (67/840)
 26–35 17% (139/840)
 36–45 14% (121/840)
 46–55 14% (118/840)
 56–65 9% (74/840)
 66–89 11% (89/840)
Malaria parasitaemia
 Overall 4% (34/834)
 Children aged 3–12 years 11% (13/120)
Schistosoma mansoni infection status 1% (7/686)
Hookworm infection status 15% (104/686)
Ascaria lumbricoides infection status 1% (8/686)
Trichuris trichiura infection status 0.2% (1/685)
Data are among participants tested for Kaposi’s sarcoma–associated herpesvirus viral 
DNA. The presence of malaria parasitaemia was determined using rapid diagnostic tests. 
Helminth status was determined from a single stool sample using the Kato Katz method.
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levels of KSHV DNA in saliva (adjusted regression coefficient 
0.46 [CI, .05–.87]; P = .027; Table 5).
DNA Detection and Antibody Levels
Individuals with detectable viral DNA in PBMCs (Supplementary 
Figure 1A) and in saliva (Supplementary Figure 1B) had higher 
IgG antibodies to the K8.1 antigen (P  <  .0001), as previously 
reported [13]. There were no differences in IgG antibody levels 
to the ORF73 antigen between individuals with or without de-
tectable viral DNA in the blood (Supplementary Figure 1C) or 
in saliva (Supplementary Figure 1D).
DISCUSSION
This is the first population-based study to report on the pres-
ence and levels of KSHV viral DNA in the blood and saliva of 
apparently healthy people across the life course. The proportion 
of individuals with detectable viral DNA in saliva was higher 
than the proportion of individuals with detectable viral DNA in 
blood, consistent with previous reports [22, 45–47]. We previ-
ously reported KSHV and EBV DNA shedding in the saliva of 
children and their mothers in Uganda, and noted that Epstein-
Barr Virus DNA was shed more frequently and at higher levels 
than KSHV [38].
Figure 2. Proportion of individuals with detectable Kaposi’s sarcoma–associated herpesvirus (KSHV) in (A) peripheral blood mononuclear cells and (B) saliva. KSHV viral 
loads were measured using real time polymerase chain reaction. Abbreviation: KSHV, Kaposi’s sarcoma–associated herpesvirus.
Table 2. Risk Factors for the Presence of Detectable Kaposi’s Sarcoma–Associated Herpesvirus DNA in Blood (Categorically)
% Detectable Viral DNA in Blood OR (95% CI) P Value Adjusteda OR (95% CI) P Value
Age group
 3–12 23% (27/120) 1  1  
 13–25 15% (26/177) 0.59 (.33–1.08)  0.63 (.33–1.17)  
 26–50 7% (20/307) 0.24 (.13–.45)  0.29 (.15–.57)  
 50+ 8% (18/227) 0.30 (.16–.57) <.0001 0.34 (.16–.72) .0014
Sex
 Female 10% (41/419) 1  1  
 Male 12% (49/406) 1.27 (.82–1.96) .294 0.89 (.55–1.45) .638
Malaria parasitaemia
 Negative 10% (83/791) 1  1  
 Positive 21% (7/34) 2.21 (.93–5.24) .071 1.59 (.64–3.95) .321
Schistosoma mansoni
 Negative 11% (77/672) 1  1  
 Positive 43% (3/7) 5.80 (1.27–26.38) .023 11.04 (2.16–56.97) .004
Hookworm
 Negative 13% (74/576) 1  1  
 Positive 6% (6/103) 0.42 (.18–.99) .048 0.41 (.16–1.04) .061
Logistic regression was used for the statistical analysis. The presence of malaria parasitaemia was determined using rapid diagnostic tests. Helminth status was determined from a single 
stool sample using the Kato Katz method.
Abbreviations: CI, confidence interval; OR, odds ratio.
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In this study, we observed no correlation between levels of KSHV 
DNA in blood and in saliva. The detection of KSHV DNA in blood 
and in saliva may reflect a reactivation of the virus or an initial in-
fection that manifests with lytic replication. Viral shedding in saliva 
leads to transmission of the virus [13], while a viral load in blood 
has been implicated in disease risk and progression [18, 23]. The 
lack of a correlation between blood and saliva viral DNA suggests 
that the mechanisms for reactivation of the virus in blood and in sa-
liva may be different. This may imply that distinct immune control 
measures are required to prevent viral reactivation in the different 
compartments. For insistence, immunoglobin A production in sa-
liva may be important for viral control in oral fluids, while T and 
natural killer cell responses may play a more pivotal role in the 
control of viral reactivation in peripheral blood. Alternatively, envi-
ronmental factors, such as plant derivates that have been shown to 
reactivate KSHV in vitro [48], may play a role in viral reactivation 
in oral fluids if chewed. Therefore, studies of immune correlates of 
KSHV DNA detection in saliva and PBMC are warranted.
Table 3. Risk Factors Associated With Increasing Levels of Kaposi’s Sarcoma–Associated Herpesvirus DNA in Blood (Continuously)
Coef (95% CI) P Value Adjusteda Coef (95% CI) P Value
Age group
 3–12 Ref  Ref  
 13–25 −0.39 (−.86 to .07)  −0.35 (−.84 to .15)  
 26–50 0.19 (−.31 to .69)  0.26 (−.30 to .83)  
 50+ −0.32 (−.83 to .19) .084 −0.06 (−.70 to .57) .160
Sex
 Female Ref  Ref  
 Male 0.10 (−.27 to .47) .594 0.21 (−.19 to .61) .292
Malaria parasitaemia
 Negative Ref  Ref  
  Positive 0.71 (.05–1.38) .036 0.79 (.07–1.50) .031
Schistosoma mansoni
 Negative Ref  Ref  
 Positive 0.17 (−.87 to 1.21) .750 −0.15 (−1.30 to 1.00) .797
Hookworm
 Negative Ref  Ref  
 Positive 0.30 (−.45 to 1.05) .79 0.37 (−.46 to 1.21) .372
Linear regression modelling was performed on log
10
 transformed KSHV DNA levels for statistical analysis. The presence of malaria parasitaemia was determined using rapid diagnostic tests. 
Helminth status was determined from a single stool sample using Kato Katz method.
Abbreviations: CI, confidence interval; Coef, linear regression coefficient; KSHV, Kaposi’s sarcoma–associated herpesvirus; Ref, reference.
aAdjusted for age, sex, malaria parasitaemia, Schistosoma mansoni, and hookworm infection status.
Table 4. Risk Factors for the Presence of Detectable Kaposi’s Sarcoma–Associated Herpesvirus DNA in Saliva (Categorical)
% Detectable Viral DNA in Saliva OR (95% CI) P Value Adjusteda OR (95% CI) P Value
Age group
 3–12 42% (50/120) 1    
 13–25 31% (55/175) 0.64 (.40–1.40)  0.61 (.37–1.02)  
 26–50 18% (56/310) 0.31 (.19–.49)  0.38 (.24–.63)  
 50+ 17% (39/231) 0.28 (.18–.47) <.0001 0.30 (.18–.54) .0001
Sex
 Female 19% (79/423) 1  1  
 Male 29% (119/407) 1.80 (1.30–2.49) <.0001 1.63 (1.14–2.34) .008
Malaria parasitaemia
 Negative 24% (188/796) 1  1  
 Positive 29% (10/34) 1.35 (.63–2.87) .439 0.98 (.44–2.16) .952
Schistosoma mansoni
 Negative 26% (174/675) 1  1  
 Positive 43% (3/70) 2.16 (.48–9.74) .317 2.43 (.51–11.52) .265
Hookworm
 Negative 27% (158/578) 1  1  
 Positive 18% (19/104) 0.59 (.35–1.009) .054 0.66 (.38–1.14) .136
Logistic regression was used for statistical analysis. The presence of malaria parasitaemia was determined using rapid diagnostic tests. Helminth status was determined from a single stool 
sample using the Kato Katz method.
Abbreviations: CI, confidence interval; Coef, linear regression coefficient.
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The proportion of KSHV DNA detected in blood and saliva 
was highest in children, compared to adults. Previous studies 
have reported a high risk of KSHV seropositivity in children 
born to KSHV-seropositive mothers [13, 35, 49]. However, se-
ropositivity in children whose mothers were seronegative has 
also been reported [49, 50]. Our current study suggests that sib-
lings or playmates may also be a major source of transmission 
to uninfected children.
High viral loads among children could be associated with 
coinfections that are very prevalent in childhood, such as 
coinfection with malaria; we also observed the highest preva-
lence of malaria parasitaemia in the same age group. We showed 
that participants with malaria parasitaemia have higher levels 
of KSHV DNA in blood, compared to those uninfected with 
malaria. This is the first study to relate malaria parasitaemia di-
rectly with KSHV load in blood. We have previously reported 
associations between malaria (parasitaemia and antibodies) 
and KSHV seroprevalence [16, 32–34]. Results from the current 
study support a potential role of malaria in KSHV pathogen-
esis. The mechanisms for the association between malaria and 
KSHV viral load could include immunomodulation and dys-
function associated with repeated malaria infections [51, 52].
In the present study, males (both men and boys) were more 
likely to shed KSHV DNA in saliva and had higher levels of 
viral DNA, compared to females (women and girls). This is con-
sistent with previous studies by us and others [31, 36, 38]. Sex 
differences in the immune controls of KSHV infections might 
contribute to the higher risk of KS in men [53, 54]. These find-
ings warrant further study.
We previously reported that high KSHV K8.1 antibody titres 
were associated with and predictive of KS risk [55]. In the cur-
rent study, we have observed that people with detectable viral 
DNA in both blood and saliva have higher IgG antibody levels 
for K8.1, but not for ORF73, when compared to individuals 
without detectable viral DNA. This association confirms our 
previous hypothesis [55]: increased lytic antibody levels reflect 
more frequent KSHV reactivation.
In summary, our data are consistent with high rates of KSHV 
transmission in rural Uganda. This might be partly attributed to 
parasite coinfections, such as coinfection with malaria, which 
interferes with immune control or makes uninfected children 
susceptible to infections. Studies investigating the mechanism 
through which malaria affects KSHV are required. Additionally, 
the characterization of protective immune responses to KSHV 
is needed to inform vaccine development and to develop strat-
egies to lower KSHV transmission in endemic areas.
Supplementary Data
Supplementary materials are available at Clinical Infectious Diseases online. 
Consisting of data provided by the authors to benefit the reader, the posted 
materials are not copyedited and are the sole responsibility of the authors, 
so questions or comments should be addressed to the corresponding author.
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